About
Wize Pharma is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including dry eye syndrome (DES) and other inflammatory conditions. Wize has in-licensed certain rights to purchase, market, sell, and distribute a formula known as LO2A, a drug developed for the treatment of DES and other ophthalmological illnesses, including CCH and Sjgrens syndrome. LO2A is currently registered and marketed in Germany and Switzerland for the treatment of DES; in Hungary for the treatment of DES, CCH, and Sjgrens; and in the Netherlands for the treatment of DES and Sjgrens. Wizes strategy involves engaging local or multinational distributors to handle the distribution of LO2A. The company has finished a phase 2 trial of LO2A for patients with CCH and is currently conducting a phase 4 study of LO2A for DES in patients with Sjgrens. LO2A was developed by Prof. Shabtay Dikstein of the Hebrew Universitys School of Pharmacy as a substitute for natural tears to lubricate and protect ocular surface tissues.